Steroid Injection vs. BioDRestore for Patients With Knee OA
- Registration Number
- NCT02767492
- Lead Sponsor
- The Hawkins Foundation
- Brief Summary
- This study will include patients who are diagnosed with knee OA and are recommended for a knee injection. Study subjects will be randomized to receive either the standard of care knee injection (steroid) or amniotic tissue injection (BioDRestore). Study subjects will be asked for permission for a baseline knee aspiration prior to the knee injection. At 6 months post-injection, knee aspirations will be taken and sent for analysis. Study subjects will be followed for 1 year post-injection to include range of motion measurements and patient-reported pain/functional outcome measurements. X-rays will also be taken at the 1-year post-injection appointment. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- Male or female, aged 18 to 80 years.
- Willing and able to give voluntary informed consent to participate in this investigation.
- Patient presents with knee osteoarthritis and Kellgren Lawrence grade 2-4 (OA diagnosed and confirmed by treating physician using standing x-ray).
- Candidate for intra-articular knee injection.
- BMI < 40
- Patients who have received intra-articular injection(s) in the last 3 months.
- Patients who have undergone arthroscopic surgery on the study knee in the past year.
- Patients who have undergone arthroplasty on the study knee.
- Ligament instability
- Diabetes (Type 1 or II)
- Inflammatory arthropathies.
- Fibromyalgia or chronic fatigue syndrome.
- Female patient who is pregnant or nursing.
- Chronic use of narcotics.
- Any other reason (in the judgment of the investigator).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
- Group - Intervention - Description - BioDRestore™ - BioD Restore - BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint. - Corticosteroid - Kenalog - Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint. 
- Primary Outcome Measures
- Name - Time - Method - Single Alpha Numeric Evaluation (SANE) - Surgery to 12 months post-op. - Percentage of normal for affected knee between 0 to 100, with 100 being a perfectly "normal" knee and 0 being a completely "abnormal" knee. - Lysholm Knee Score - Surgery to 12 months post-op. - Patient reported knee function scores on a scale of 0-100, with 100 being a excellent outcome indicating no symptoms. - Visual Analog Pain Score - Surgery through 12 months post-op/ - Patient reported level of pain on a scale of 0-10, with 10 being extreme pain and 0 being no pain. - Veterans Rand 12 Item Health Survey - Sugery to 12 months post-op - Patient reported quality of life. Score contains a physical component and mental component score. Both scales are continuous and values range from 0 to 70, with higher scoring indicating higher physical and mental component scores - Knee Injury and Osteoarthritis Outcome Score (KOOS) - Surgery to 12 months post op - Knee outcome measure assessed via Knee Injury and Osteoarthritis Outcome Score (KOOS) on a scale of 0 to 100. The higher score of 100 indicates a fully functional knee without knee pain or problems. 
- Secondary Outcome Measures
- Name - Time - Method 
Trial Locations
- Locations (1)
- Steadman Hawkins Clinic of the Carolinas 🇺🇸- Greenville, South Carolina, United States Steadman Hawkins Clinic of the Carolinas🇺🇸Greenville, South Carolina, United States
